Leber Hereditary Optic Neuropathy (LHON): A Complete Patient Guide

11 Aug Leber Hereditary Optic Neuropathy (LHON): A Complete Patient Guide

Medically reviewed by Dr. Prashant Tyagi (Stem Cell Biotechnology Specialist, 10+ years) and Dr. B. N. Singh (General Physician, MBBS MS General Surgery, 30+ years)

Leber’s Hereditary Optic Neuropathy, commonly known as LHON, is a condition many patients have never heard of until a sudden, unexplained loss of central vision leads to diagnosis. Because it’s both genetically distinct and often misunderstood, here is a complete, honest guide to what LHON is, how it’s inherited, and what patients typically need to know.

What LHON Actually Is

LHON is an inherited condition that causes damage to retinal ganglion cells – the nerve cells that form the optic nerve and carry visual information from the eye to the brain. Unlike many other inherited eye conditions, LHON typically causes sudden or rapidly progressive vision loss, usually affecting one eye first and the other within weeks to months, rather than a slow decline over years.

The Genetics Behind LHON

LHON is caused by mutations in mitochondrial DNA, which is inherited exclusively from the mother – meaning it does not follow the typical inheritance patterns of nuclear gene conditions. This is a critical distinction: a mother carrying a LHON mutation can pass it to all of her children, but only some will develop symptoms, and the condition affects men more frequently and often more severely than women, for reasons researchers are still working to fully understand.

Who Is Typically Affected

LHON most commonly presents in young adults, typically between the ages of 15 and 35, though onset can occur outside this range. Not everyone carrying a LHON mutation develops symptoms – a phenomenon called incomplete penetrance – and certain environmental factors, including smoking and heavy alcohol use, have been associated with a higher likelihood of symptom onset in genetically susceptible individuals.

Symptoms Patients Typically Notice

• Sudden, painless blurring or loss of central vision, often starting in one eye
• Vision loss in the second eye typically following within weeks to months
• Difficulty with colour vision, particularly reds and greens
• Preserved peripheral vision in most cases, even as central vision is significantly affected

Because the onset is sudden and painless, many patients initially assume something acute and reversible is happening, which can delay appropriate diagnosis if LHON is not considered early.

How LHON Is Diagnosed

Diagnosis typically involves a detailed eye examination, visual field testing, and optical coherence tomography (OCT) to assess the retinal nerve fibre layer, alongside genetic testing to confirm one of the mitochondrial DNA mutations associated with LHON. Because LHON can sometimes be mistaken for optic neuritis or other causes of sudden vision loss, genetic confirmation is an important step in reaching an accurate diagnosis.

Questions Worth Asking Your Doctor

• Has genetic testing confirmed which specific mitochondrial mutation is involved?
• What does this mean for other family members, particularly on the maternal side?
• Are there lifestyle factors, such as smoking or alcohol use, that I should address given this diagnosis?
• What monitoring or supportive options are appropriate for my specific case and stage?

What This Means in Practice

Because LHON currently has no universally established cure, care generally focuses on confirming an accurate genetic diagnosis, counselling affected families on inheritance patterns and risk, addressing modifiable factors that may influence symptom onset, and discussing supportive or emerging treatment options – including regenerative approaches – appropriate to the individual’s specific mutation and disease stage.

Government & Regulatory References

• National Policy for Rare Diseases, 2021 – Ministry of Health and Family Welfare, Government of India – LHON is classified as a rare inherited mitochondrial disorder, and this policy outlines India’s framework for diagnosis, management, and support for such conditions.
• Evidence-Based Status of Stem Cell Therapy for Human Diseases – Indian Council of Medical Research (ICMR)